Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology
NCT ID: NCT02727673
Last Updated: 2016-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1000 participants
OBSERVATIONAL
2012-12-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
NCT02416635
Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform
NCT05242237
Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer
NCT04688606
Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence
NCT02032368
A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer
NCT05371873
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
healthy volunteers
matched group
No interventions assigned to this group
hepatitis cirrhosis
negative group
No interventions assigned to this group
hepatocellular carcinoma
patients with primary HCC
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal.
3. Patients who can understand this trial and have signed information consent
Exclusion Criteria
2. Impossible to come to our hospital for physical examination regularly;
3. Patients with other diseases which may affect the treatment mentioned
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eastern Hepatobiliary Surgery Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ShenFeng
vice president of the Eastern Hepatobiliary Surgery Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eastern hepatobilliary surgery hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZD201200102-P1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.